SEC Form 4 · accession 0001144204-17-059793
Sorrento Therapeutics, Inc. · SRNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Lemus
Director
Period of report
Nov 14, 2017
Accepted (ET)
Nov 16, 2017 · 7:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000850261
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $2.30 | Nov 14, 2017 | A | 35,000 | A | — | Nov 14, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F11/12 of the original number of shares subject to this option is immediately vested and exercisable. 1/12 of the original number of shares subject to this option shall vest and become exercisable on November 26, 2017 and 1/12 of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service on the Issuer's board of directors on each such date.